U.S. markets open in 5 hours 21 minutes
  • S&P Futures

    4,477.00
    +2.75 (+0.06%)
     
  • Dow Futures

    34,803.00
    +54.00 (+0.16%)
     
  • Nasdaq Futures

    15,522.75
    +5.00 (+0.03%)
     
  • Russell 2000 Futures

    2,228.30
    +0.40 (+0.02%)
     
  • Crude Oil

    72.17
    -0.44 (-0.61%)
     
  • Gold

    1,761.80
    +5.10 (+0.29%)
     
  • Silver

    22.96
    +0.17 (+0.73%)
     
  • EUR/USD

    1.1783
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.46
    +0.28 (+1.54%)
     
  • GBP/USD

    1.3796
    -0.0000 (-0.00%)
     
  • USD/JPY

    109.9330
    +0.2150 (+0.20%)
     
  • BTC-USD

    47,822.95
    -504.71 (-1.04%)
     
  • CMC Crypto 200

    1,220.59
    -12.70 (-1.03%)
     
  • FTSE 100

    7,049.52
    +22.04 (+0.31%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Oncolytics Biotech (ONCY) Enters Overbought Territory

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Oncolytics Biotech Inc. ONCY has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because ONCY is now in overbought territory with an RSI value of 70.23.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet ONCY’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions Oncolytics Biotech’s stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of ONCY’s prospects for the near term.

Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for ONCY’s has also been on a downward trend over the same time period too, as the estimates have fallen 8.7% over the last two months.

If this wasn’t enough, Oncolytics Biotech also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Oncolytics Biotech Inc. (ONCY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.